Literature DB >> 7715704

Noradrenaline is essential for mouse fetal development.

S A Thomas1, A M Matsumoto, R D Palmiter.   

Abstract

Catecholamines such as noradrenaline and adrenaline have been implicated in numerous physiological processes but, although catecholamine synthesis begins at mid-gestation, previous studies have provided little evidence for any role in early development. Furthermore, there are several case reports of humans with noradrenaline deficiency. To investigate this, we use gene targeting to produce mice lacking dopamine beta-hydroxylase and therefore unable to synthesize noradrenaline or adrenaline. We report here that in heterozygous mothers, most homozygous embryos died in utero, and only about 5% reached adulthood. Survival probably depends on catecholamine transfer across the placenta because, in homozygous mothers, all embryos die in utero. Mortality was due to lack of noradrenaline in utero because it could be prevented by treatment with dihydroxyphenylserine, a precursor that can be converted to noradrenaline in the absence of dopamine beta-hydroxylase. Mutant embryos had a histological phenotype similar to that of embryos deficient in tyrosine hydroxylase, suggesting that death might be due to cardiovascular failure.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7715704     DOI: 10.1038/374643a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  160 in total

Review 1.  Lessons learned from gene targeting and transgenesis for adrenal physiology and disease.

Authors:  A Böttner; S R Bornstein
Journal:  Rev Endocr Metab Disord       Date:  2001-08       Impact factor: 6.514

2.  Mining copper transport genes.

Authors:  N C Andrews
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-05       Impact factor: 11.205

Review 3.  Monoamine oxidases in development.

Authors:  Chi Chiu Wang; Ellen Billett; Astrid Borchert; Hartmut Kuhn; Christoph Ufer
Journal:  Cell Mol Life Sci       Date:  2012-07-11       Impact factor: 9.261

4.  Mice lacking adrenergic signaling have normal cochlear responses and normal resistance to acoustic injury but enhanced susceptibility to middle-ear infection.

Authors:  Stéphane F Maison; Mina Le; Erik Larsen; Suh-Kyung Lee; John J Rosowski; Steven A Thomas; M Charles Liberman
Journal:  J Assoc Res Otolaryngol       Date:  2010-05-26

5.  L-threo 3,4-dihydroxyphenylserine treatment during mouse perinatal and rat postnatal development does not alter the impact of dietary copper deficiency.

Authors:  Joshua W Pyatskowit; Joseph R Prohaska
Journal:  Nutr Neurosci       Date:  2005-06       Impact factor: 4.994

6.  Norepinephrine-deficient mice have increased susceptibility to seizure-inducing stimuli.

Authors:  P Szot; D Weinshenker; S S White; C A Robbins; N C Rust; P A Schwartzkroin; R D Palmiter
Journal:  J Neurosci       Date:  1999-12-15       Impact factor: 6.167

7.  The full expression of fasting-induced torpor requires beta 3-adrenergic receptor signaling.

Authors:  Steven J Swoap; Margaret J Gutilla; L Cameron Liles; Ross O Smith; David Weinshenker
Journal:  J Neurosci       Date:  2006-01-04       Impact factor: 6.167

8.  Elimination of zinc from synaptic vesicles in the intact mouse brain by disruption of the ZnT3 gene.

Authors:  T B Cole; H J Wenzel; K E Kafer; P A Schwartzkroin; R D Palmiter
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

9.  L-threo-dihydroxyphenylserine corrects neurochemical abnormalities in a Menkes disease mouse model.

Authors:  Anthony Donsante; Patricia Sullivan; David S Goldstein; Lauren R Brinster; Stephen G Kaler
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

10.  Alpha2-adrenoceptor blockade accelerates the neurogenic, neurotrophic, and behavioral effects of chronic antidepressant treatment.

Authors:  Sudhirkumar U Yanpallewar; Kimberly Fernandes; Swananda V Marathe; Krishna C Vadodaria; Dhanisha Jhaveri; Karen Rommelfanger; Uma Ladiwala; Shanker Jha; Verena Muthig; Lutz Hein; Perry Bartlett; David Weinshenker; Vidita A Vaidya
Journal:  J Neurosci       Date:  2010-01-20       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.